Speakers

Expand/Collapse

Nicolas Ferry
Chief Development Officer
Horama

Day Two

Thursday 13th December 2018

4:35 pm | Q&A Panel Discussion

3:35 pm | Understanding the Pre-Clinical Regulators’ Expectations for Gene Therapy Trials

Peter Campochiaro
Director, Retinal Cell & Molecular Laboratory; Professor of Ophthalmology
Johns Hopkins University School of Medicine

Sanford Boye
Director of Vector Core, Powell Gene Therapy Center University of Florida
Chief Technology Officer Atsena Therapeutics

Shannon Boye
Founder & Chief Scientific Officer
Atsena Therapeutics

Day One

Thursday 13th December 2018

5:00 pm | Q&A Panel Discussion

4:20 pm | Gene Therapy for GUCY2D Leber Congenital Amaurosis (LCA1)

Abraham Scaria
Chief Scientific Offier
IVERIC Bio

Day One

Thursday 13th December 2018

11:50 am | Q&A Panel Discussion

11:30 am | The Single AAV-minigene Approach for Delivery of Large Genes to the Retina • AAV vectors are efficacious for gene delivery to the retina

Aniz Girach
Chief Medical Officer
ProQR

Claire Gelfman
Chief Scientific Officer
Foundation Fighting Blindness

Day Two

Thursday 13th December 2018

4:35 pm | Q&A Panel Discussion

4:15 pm | Gene Agnostic Approaches for the Treatment of Inherited Retinal Diseases

Daniel Chung
Chief Medical Officer
SparingVision

Day One

Thursday 13th December 2018

3:00 pm | Q&A Panel Discussion

2:40 pm | Defining Novel Endpoints for IRDs

Day Two

Thursday 13th December 2018

2:00 pm | Q&A Panel Discussion

1:00 pm | Gene Agnostic Approaches Targeting Later Stage Diseases for Photoreceptor Function

Dominik Fischer
Principal Investigator & Consultant Ophthalmic Surgeon
Oxford Eye Hospital

Eric Kelsic
Chief Executive Officer
Dyno Therapeutics

Day Two

Thursday 13th December 2018

11:30 am | Q&A Panel Discussion

10:00 am | Machine Guided Capsid Engineering for Ocular Diseases

Francine Behar-Cohen
Founder & Chief Innovation Officer
Eyevensys

Day Two

Thursday 13th December 2018

11:30 am | Q&A Panel Discussion

10:50 am | Non-Viral Vectors for Lower Cost Manufacturing & Immune Mitigation

Gaelle Lefevre
Head of Project Management
HORAMA

Gil Carrasquinho
Vice President & Head of Cell Therapy
Santen

Day Two

Thursday 13th December 2018

2:00 pm | Q&A Panel Discussion

1:40 pm | The Potential of Intravitreal Human Retinal Progenitor Cells (hRPCs) in Inherited Retinal Disorders

Glenn Yiu
Associate Professor
University of California, Davis

Day Two

Thursday 13th December 2018

9:00 am | Q&A Panel Discussion

8:40 am | Host Immunity after Suprachoroidal AAV in Nonhuman Primates

Jacque Duncan
Professor, Clinical Ophthalmology
University of California San Fransisco

Day One

Thursday 13th December 2018

3:00 pm | Q&A Panel Discussion

2:20 pm | Outcome Measures for Clinical Trials In Inherited Retinal Degenerations

Jake Ternent
Patient
Luxturna

Day One

Thursday 13th December 2018

4:00 pm | A Patient’s Perspective: Jake’s Story & Q&A Session

José-Alain Sahel
Chairman & Professor, Ophthalmology
University of Pittsburgh

Day Two

Thursday 13th December 2018

9:00 am | Q&A Panel Discussion

8:20 am | Retinitis Pigmentosa to Dry AMD: A Clinical Update on Optogenetic Therapy

Magali Taiel
Chief Medical Officer
GenSight Biologics

Day Two

Thursday 13th December 2018

4:35 pm | Q&A Panel Discussion

3:15 pm | Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy (LHON): Regulatory Considerations: US & Europe Regulators

Nadia Waheed
Associate Professor in Ophthalmology Tufts University Medical School
Chief Medical Officer Gyroscope Therapeutics

Day One

Thursday 13th December 2018

9:35 am | Q&A Panel Discussion

8:35 am | Rare Vs Common Disorders: Structural & Functional Endpoints for Clinical Trials in AMD & Diabetic Retinopathy

Sheila Nirenberg
Professor & Founder
Bionic Sight

Day Two

Thursday 13th December 2018

2:00 pm | Q&A Panel Discussion

1:20 pm | Positive Interim Results in Bionic Sight’s Optogenetic Gene Therapy Trial

Stavros Ntogiako
Head of Luxturna & Gene Therapy
Novartis

Day One

Thursday 13th December 2018

9:35 am | Q&A Panel Discussion

9:15 am | Approaching Commercialization Hurdles: Other Treatments Available, Pricing & Reimbursement

Stephen Poor
Director of External Opportunities & Translational Biomarkers
Novartis

Day Two

Thursday 13th December 2018

2:30 pm | Panel: Discussing Pharma Partnering & Collaboration: Challenges & Opportunities

Steve Pakola
Chief Medical Officer
REGENXBIO

Day One

Thursday 13th December 2018

5:00 pm | Q&A Panel Discussion

4:40 pm | Comparing Clinical Progress with Different Administration Routes

Stylianos Michalakis
Co-founder & Chief Scientific Advisor
ViGeneron

Day Two

Thursday 13th December 2018

11:30 am | Q&A Panel Discussion

11:10 am | Retinal Gene Therapy: Novel Vector Technologies

Sue Washer
Chief Executive Officer
AGTC

Thomas Ciulla
Vitreoretinal Medicine & Surgery, Chief Medical Officer & Chief Development Officer
Clearside Biomedical Inc.

Day One

Thursday 13th December 2018

9:35 am | Q&A Panel Discussion

8:55 am | Evaluating the Promise of Suprachoroidal Delivery for Retinal Expression

Ying Kai Chan
Visiting Scholar
Harvard University

Day Two

Thursday 13th December 2018

9:00 am | Q&A Panel Discussion

8:00 am | Landscape of Ocular Gene Therapy Immunogenicity & Vector Strategies to Overcome Inflammation

Udo Maier
Head of Research Beyond Borders Europe
Boehringer Ingelheim

Day Two

Thursday 13th December 2018

2:30 pm | Panel: Discussing Pharma Partnering & Collaboration: Challenges & Opportunities

David Dismuke
Chief Technical Officer
Forge Biologics

Day Two

Thursday 13th December 2018

10:20 am | Efficient Gene Therapy Manufacturing for Ocular Diseases

Hema Ramkumar
Chief Executive Officer, Founder
Oculogenex

Day One

Thursday 13th December 2018

11:50 am | Q&A Panel Discussion

11:20 am | Preclinical Validation of a Novel Modifier Ocular Gene Therapy for the Prevention of Geographic Atrophy in Patients with Dry Macular Degeneration

Snehal Naik
Regulatory Policy Leader
Spark Therapeutics

Day Two

Thursday 13th December 2018

3:55 pm | Regulatory Considerations for Gene Therapy Development” covering the following topics:

4:35 pm | Q&A Panel Discussion

Tara Moore
Professor of Personalized Medicine, Ulster University; Chief of Research & Innovation
Avellino

Day One

Thursday 13th December 2018

8:05 am | Progressing Multiple Gene Therapy Paths for Avellino Corneal Dystrophy

9:35 am | Q&A Panel Discussion

Ryan Boyd
Senior Research Scientist, Ophthalmology
Charles River Laboratories

Kanmin Xue
Wellcome Trust Clinician Scientist Fellow & Honorary Consultant Vitreoretinal Surgeon
University of Oxford

Caroline Xu
Chief Executive Officer
Vigeneron

Day Two

Thursday 13th December 2018

2:30 pm | Panel: Discussing Pharma Partnering & Collaboration: Challenges & Opportunities